Current and Long-Term Liabilities (Details) (USD $)	3 Months Ended			12 Months Ended					12 Months Ended
	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011	Dec. 31, 2012 Takeda	Dec. 31, 2010 Takeda	Dec. 31, 2011 Takeda	Dec. 31, 2012 Other short-term deferred revenues	Dec. 31, 2011 Other short-term deferred revenues	Dec. 31, 2008 3SBio	Dec. 31, 2012 3SBio	Dec. 31, 2011 3SBio
Accrued Expenses
Clinical, manufacturing and regulatory consulting fees and expenses	$ 7,737,000		$ 11,468,000
Salaries, bonuses, and other compensation	5,236,000		5,924,000
Commercial rebates, fees and returns	3,448,000		5,943,000
Professional, license, and other fees and expenses	1,719,000		1,966,000
Restructuring expense	1,383,000		2,366,000
Commercial consulting fees and expenses	815,000		1,249,000
Total accrued expenses	20,338,000		28,916,000
Deferred Revenues
Total short-term deferred revenues	9,104,000		6,346,000	8,854,000		6,096,000	250,000	250,000
Total long-term deferred revenues	50,350,000		45,196,000	49,350,000		44,196,000				1,000,000	1,000,000
Upfront payment received					60,000,000				1,000,000
Reimbursement revenues					1,000,000
Initial term of license									13 years
Amortization period for recognizing nonsubstantive milestone payments					10 years
Milestone payments received under agreement related to commercial launches				18,000,000
Milestone revenue recognized	5,000,000	15,000,000		5,000,000
Deferred revenue recorded				$ 13,000,000